Premium
SU‐GG‐J‐122: Therapeutic Efficacy of 198Au Nanoparticles Using a Canine Model of Prostate Cancer
Author(s) -
Kannan R,
Boote E,
Khan P,
Cutler C,
Jurisson S,
Katti K,
Chanda N,
Shukla R,
Axiak S,
Lattimer J,
Henry C,
Zambre A,
Katti K
Publication year - 2010
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.3468346
Subject(s) - medicine , prostate cancer , clinical trial , prostate , therapeutic effect , cancer , radiation therapy , clinical efficacy , chemotherapy , therapeutic index , therapeutic approach , oncology , pharmacology , drug , disease
As part of our efforts toward clinical translation of GA‐ 198 AuNP, our studies are focused on therapeutic efficacy of nanoparticulate GA 198 AuNP agent in dogs with prostatic carcinoma. The overall goal is to gain clinical insights on therapeutic efficacy of GA 198 AuNP in a large animal model. We have performed a phase I clinical trial using GA‐AuNP administered intravenously or intra‐tumoral injection or infusion. CT scans were performed prior to injection and 24 hours post injection in 3 of the 4 dogs. Following injections, dogs were allowed further treatment as recommended by the primary attending clinician. Four dogs have been treated to date. Complications related to GA‐AuNP treatment were not observed, and all 4 dogs received adjunctive treatment with radiation therapy and/ or chemotherapy. These preliminary studies have clearly provided compelling evidence on the therapeutic potential of biocompatible GA‐AuNP for their utility as novel therapeutic agents in treating various types of inoperable solid tumors. Intra‐tumoral and intravenous administration of GA‐AuNP is safe in dogs with spontaneously occurring tumors. As further therapeutic efficacy studies continue, the outcome of this clinical trial in a large animal model will generate therapeutic efficacy data which will be used for filing IND application for Phase I clinical trial studies. This clinical translation effort provides significant advances in terms to deliver optimum therapeutic payloads into prostate cancers with subsequent reduction in tumor volume, thus may effectively reduce/eliminate the need for surgical resection. This presentation will include details of clinical translation of GA 198 AuNP in prostate tumor bearing dogs.